[{"id":"ef9f9bd0-273f-42be-ab92-31c003721bbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01861106","created_at":"2021-01-18T08:19:16.098Z","updated_at":"2025-02-25T12:26:02.331Z","phase":"Phase 2","brief_title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","source_id_and_acronym":"NCT01861106","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" GATA2","pipe":" | ","alterations":" GATA2 mutation","tags":["GATA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GATA2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • busulfan • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 144","initiation":"Initiation: 07/24/2013","start_date":" 07/24/2013","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-02-24"},{"id":"38aae3c4-f386-4a60-a95e-c6b46ee44656","acronym":"","url":"https://clinicaltrials.gov/study/NCT05656248","created_at":"2022-12-19T14:58:46.031Z","updated_at":"2025-02-25T14:41:44.924Z","phase":"Phase 2","brief_title":"Study of CPX-351 (VYXEOS) in Individuals \u003c 22 Years With Secondary Myeloid Neoplasms","source_id_and_acronym":"NCT05656248","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" TP53 • NF1 • RUNX1 • ETV6 • CEBPA • CD4 • MECOM • GATA2 • ANKRD26","pipe":"","alterations":" ","tags":["TP53 • NF1 • RUNX1 • ETV6 • CEBPA • CD4 • MECOM • GATA2 • ANKRD26"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 01/17/2023","start_date":" 01/17/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-02-14"},{"id":"421063e1-092c-4069-8aae-f069c4e61471","acronym":"","url":"https://clinicaltrials.gov/study/NCT01174108","created_at":"2021-01-18T04:41:02.291Z","updated_at":"2025-02-25T15:25:06.019Z","phase":"Phase 2","brief_title":"Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells","source_id_and_acronym":"NCT01174108","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" TERT • GATA2","pipe":" | ","alterations":" TERT mutation • GATA2 mutation","tags":["TERT • GATA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TERT mutation • GATA2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/10/2010","start_date":" 12/10/2010","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-02-11"},{"id":"ac72e48c-1524-449b-acbb-64797b142680","acronym":"","url":"https://clinicaltrials.gov/study/NCT04965597","created_at":"2021-07-16T13:53:25.569Z","updated_at":"2025-02-25T16:32:32.043Z","phase":"Phase 2","brief_title":"Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)","source_id_and_acronym":"NCT04965597","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • GATA2 • HLA-B • HLA-C","pipe":" | ","alterations":" LDH elevation","tags":["HLA-DRB1 • HLA-DQB1 • GATA2 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate • fludarabine IV • busulfan • Grafapex (treosulfan) • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 04/19/2022","start_date":" 04/19/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-07"},{"id":"d2fff3d6-ffea-4d7d-80f3-4801459b6711","acronym":"","url":"https://clinicaltrials.gov/study/NCT04659616","created_at":"2021-01-19T20:42:17.932Z","updated_at":"2024-07-02T16:35:10.819Z","phase":"Phase 1","brief_title":"Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT04659616","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation","tags":["TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Pemazyre (pemigatinib) • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-09"},{"id":"b62639b3-3bfc-4f4f-81ac-2892933d901a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05115630","created_at":"2021-11-10T14:13:02.708Z","updated_at":"2024-07-02T16:35:19.132Z","phase":"Phase 1/2","brief_title":"Off-the-shelf NK Cells + SCT for Myeloid Malignancies","source_id_and_acronym":"NCT05115630","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • FLT3 • ABL1 • BCR • NPM1 • RUNX1 • ASXL1 • KMT2A • MECOM • NUP214 • GATA2 • DEK","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • MLL rearrangement • Chr del(5q) • FLT3 wild-type","tags":["TP53 • FLT3 • ABL1 • BCR • NPM1 • RUNX1 • ASXL1 • KMT2A • MECOM • NUP214 • GATA2 • DEK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • MLL rearrangement • Chr del(5q) • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • mesna • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 04/08/2022","start_date":" 04/08/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-02-16"},{"id":"0f841029-f2ce-4cb1-849c-75709569b46f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03613532","created_at":"2021-03-05T16:52:31.672Z","updated_at":"2024-07-02T16:35:22.047Z","phase":"Phase 1","brief_title":"Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN","source_id_and_acronym":"NCT03613532","lead_sponsor":"Jacqueline Garcia, MD","biomarkers":" KRAS • TP53 • FLT3 • ABL1 • NRAS • BCR • BCL2 • NPM1 • NF1 • RUNX1 • SF3B1 • ASXL1 • KMT2A • PTPN11 • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • DEK • RIT1 • ZRSR2","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • NRAS mutation • RUNX1 mutation • RAS mutation • ASXL1 mutation • CBL mutation • MLL rearrangement • U2AF1 mutation • Chr del(5q) • FLT3 wild-type","tags":["KRAS • TP53 • FLT3 • ABL1 • NRAS • BCR • BCL2 • NPM1 • NF1 • RUNX1 • SF3B1 • ASXL1 • KMT2A • PTPN11 • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • DEK • RIT1 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • NRAS mutation • RUNX1 mutation • RAS mutation • ASXL1 mutation • CBL mutation • MLL rearrangement • U2AF1 mutation • Chr del(5q) • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Inqovi (decitabine/cedazuridine) • fludarabine IV • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/24/2018","start_date":" 10/24/2018","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-01-26"},{"id":"ee79acb6-a7a2-420e-8c81-cb89ac6094da","acronym":"","url":"https://clinicaltrials.gov/study/NCT03058588","created_at":"2021-01-18T15:03:55.450Z","updated_at":"2024-07-02T16:35:42.278Z","phase":"","brief_title":"Next Generation Sequencing (NGS) in Familial Acute Myeloid Leukemia and Myelodisplastic Syndromes","source_id_and_acronym":"NCT03058588","lead_sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","biomarkers":" TERT • RUNX1 • ETV6 • GATA2 • ANKRD26","pipe":" | ","alterations":" ETV6 mutation","tags":["TERT • RUNX1 • ETV6 • GATA2 • ANKRD26"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ETV6 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 02/09/2017","start_date":" 02/09/2017","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-07-21"},{"id":"9aebc143-6452-41c7-82b0-b0dff845f7ed","acronym":"MORE","url":"https://clinicaltrials.gov/study/NCT05796570","created_at":"2023-04-03T14:03:12.035Z","updated_at":"2024-07-02T16:35:50.039Z","phase":"Phase 2","brief_title":"A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies","source_id_and_acronym":"NCT05796570 - MORE","lead_sponsor":"Franziska Wachter","biomarkers":" RUNX1 • ETV6 • DDX41 • GATA2 • ANKRD26","pipe":" | ","alterations":" RUNX1 mutation • DDX41 mutation • GATA2 mutation • ETV6 mutation","tags":["RUNX1 • ETV6 • DDX41 • GATA2 • ANKRD26"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1 mutation • DDX41 mutation • GATA2 mutation • ETV6 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 04/19/2023","start_date":" 04/19/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2023-04-20"},{"id":"73e97b9d-0254-43f8-997d-ea880735e4cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03311815","created_at":"2021-01-18T16:21:28.250Z","updated_at":"2024-07-02T16:36:34.554Z","phase":"","brief_title":"Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.","source_id_and_acronym":"NCT03311815","lead_sponsor":"PETHEMA Foundation","biomarkers":" KRAS • TP53 • FLT3 • NRAS • IDH1 • IDH2 • NPM1 • DNMT3A • JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • PTPN11 • SRSF2 • WT1 • U2AF1 • CEBPA • SETBP1 • GATA2","pipe":" | ","alterations":" U2AF1 mutation","tags":["KRAS • TP53 • FLT3 • NRAS • IDH1 • IDH2 • NPM1 • DNMT3A • JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • PTPN11 • SRSF2 • WT1 • U2AF1 • CEBPA • SETBP1 • GATA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e U2AF1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 900","initiation":"Initiation: 10/06/2017","start_date":" 10/06/2017","primary_txt":" Primary completion: 10/15/2019","primary_completion_date":" 10/15/2019","study_txt":" Completion: 10/15/2019","study_completion_date":" 10/15/2019","last_update_posted":"2021-02-16"},{"id":"eb38da98-388d-47b0-b07d-0f89209aaf70","acronym":"","url":"https://clinicaltrials.gov/study/NCT00923364","created_at":"2021-01-18T03:34:28.566Z","updated_at":"2024-07-02T16:36:48.730Z","phase":"Phase 2","brief_title":"Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC","source_id_and_acronym":"NCT00923364","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HLA-DRB1 • CD34 • HLA-DQB1 • GATA2 • HLA-B • HLA-C","pipe":" | ","alterations":" GATA2 mutation","tags":["HLA-DRB1 • CD34 • HLA-DQB1 • GATA2 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GATA2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 05/07/2009","start_date":" 05/07/2009","primary_txt":" Primary completion: 06/12/2014","primary_completion_date":" 06/12/2014","study_txt":" Completion: 02/26/2017","study_completion_date":" 02/26/2017","last_update_posted":"2020-03-12"},{"id":"f887d510-0878-4a46-85d9-281df4450717","acronym":"AMICUS","url":"https://clinicaltrials.gov/study/NCT02804984","created_at":"2021-01-18T13:45:14.737Z","updated_at":"2024-07-02T16:37:08.315Z","phase":"","brief_title":"Identification of Molecular Defects in Idiopathic Cytopenia of Undetermined Significance","source_id_and_acronym":"NCT02804984 - AMICUS","lead_sponsor":"Centre Hospitalier Universitaire, Amiens","biomarkers":" KRAS • IDH1 • IDH2 • DNMT3A • JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • U2AF1 • GATA2 • ZRSR2","pipe":"","alterations":" ","tags":["KRAS • IDH1 • IDH2 • DNMT3A • JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • U2AF1 • GATA2 • ZRSR2"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 07/01/2019","primary_completion_date":" 07/01/2019","study_txt":" Completion: 07/01/2019","study_completion_date":" 07/01/2019","last_update_posted":"2018-08-03"}]